Bush Campaign Ads: Brought to You by ... Special Interests

Public Citizen has released a report outlining who helped pay for the Bush administration's campaign ads and what favors they have received during his presidency. Bush backers include the finance, real estate, communications, energy, health care, and insurance industries. The report also lists the tax breaks, regulatory changes, legislative favors and plum appointments Bush has given his backers.


Halliburton's 'Bizarre Media Strategy'

"The chief executive of the Halliburton Company, Dave Lesar,
never imagined that he would be the star of his own
television commercial. But there he is, on the airwaves in
Washington and Houston, assuring viewers that his company
has billions of dollars in contracts to rebuild Iraq and
feed American troops 'because of what we know, not who we
know.' The unnamed 'who' is, of course, Vice President Dick
Cheney, Halliburton's chief executive from 1995 to 2000. ... The advertising, Mr. Lesar added, will continue until the


Medicare For Lobbyists

"Rep. Billy Tauzin delivered a $540 billion prescription-drug benefit for Medicare. Now, the Louisiana Republican is leaving Congress for a $2 million-a-year job in the drug industry. When it comes to exposing your principles, Rep. Tauzin makes Janet Jackson look coy," the Palm Beach Post writes. Tauzin, who chaired the House Science and Commerce Committee, pushed through the early morning passage of the Medicare bill in December.


Bush Administration Protects Chemical Industy

"Last year the Bush Administration encouraged American chemical companies to lobby against European efforts to strengthen the regulation of thousands of chemicals contained in household, industrial and personal products," writes. "When the chemical industry was slow to respond, Administration officials took it upon themselves to launch 'an unusually aggressive campaign' to pressure the European Union into watering down its comprehensive reform efforts. Documents uncovered by the Environmental Health Fund, using the Freedom of Information Act, showed the U.S.


Drug Researcher Continues To Challenge Industry Claims

A Canadian professor of pediatrics and medicine vows to continue speaking out on the risk of a drug used to treat thalassemia, a hereditary blood disorder. Dr. Nancy Olivieri lost her attempt to get her research on the harmful side effects of deferiprone looked at by the committee for proprietary and medicinal products (CPMP) that regulates drugs in Europe. "This ruling guarantees that only a drug company attempting to sell a drug will control the content of the scientific data submitted or not submitted to the European CPMP," she said.



Subscribe to Corporations